Stay updated on Immunotherapy with TIL in Metastatic Melanoma Clinical Trial
Sign up to get notified when there's something new on the Immunotherapy with TIL in Metastatic Melanoma Clinical Trial page.

Latest updates to the Immunotherapy with TIL in Metastatic Melanoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe ClinicalTrials.gov record for the metastatic melanoma immunotherapy study is displayed, with study details, participant eligibility, treatment arms, and reported outcomes.SummaryDifference89%

- Check16 days agoChange DetectedThe footer now identifies the site as revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check23 days agoChange DetectedA notice about NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence” appears above the ClinicalTrials.gov page. The study record remains unavailable behind a 403 error.SummaryDifference1%

- Check30 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check37 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check58 days agoChange DetectedA new revision tag, Revision: v3.7.0, was added. Several core study documents and links, including the Informed Consent Form, Study Protocol and SAP, IPD sharing information, and publications, were removed from the record, reducing access to key materials and study context.SummaryDifference24%

Stay in the know with updates to Immunotherapy with TIL in Metastatic Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immunotherapy with TIL in Metastatic Melanoma Clinical Trial page.